FR18C1008I2 - CLADRIBINE DOSAGE REGIMEN FOR THE TREATMENT OF MULTIPLE SCLEROSIS - Google Patents
CLADRIBINE DOSAGE REGIMEN FOR THE TREATMENT OF MULTIPLE SCLEROSISInfo
- Publication number
- FR18C1008I2 FR18C1008I2 FR18C1008C FR18C1008C FR18C1008I2 FR 18C1008 I2 FR18C1008 I2 FR 18C1008I2 FR 18C1008 C FR18C1008 C FR 18C1008C FR 18C1008 C FR18C1008 C FR 18C1008C FR 18C1008 I2 FR18C1008 I2 FR 18C1008I2
- Authority
- FR
- France
- Prior art keywords
- cladribine
- treatment
- multiple sclerosis
- dosage regimen
- regimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63866904P | 2004-12-22 | 2004-12-22 | |
| EP04106909 | 2004-12-22 | ||
| EP05823474A EP1827461B1 (en) | 2004-12-22 | 2005-12-20 | Cladribine regimen for treating multiple sclerosis |
| PCT/EP2005/056954 WO2006067141A1 (en) | 2004-12-22 | 2005-12-20 | Cladribine regimen for treating multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR18C1008I1 FR18C1008I1 (en) | 2018-03-30 |
| FR18C1008I2 true FR18C1008I2 (en) | 2019-03-01 |
Family
ID=36227798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR18C1008C Active FR18C1008I2 (en) | 2004-12-22 | 2018-02-14 | CLADRIBINE DOSAGE REGIMEN FOR THE TREATMENT OF MULTIPLE SCLEROSIS |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7713947B2 (en) |
| EP (6) | EP1827461B1 (en) |
| JP (7) | JP5795456B2 (en) |
| KR (1) | KR20070091662A (en) |
| AR (1) | AR052830A1 (en) |
| AU (2) | AU2005318190B2 (en) |
| BR (1) | BRPI0517132B8 (en) |
| CA (2) | CA2588966C (en) |
| CY (3) | CY1112614T1 (en) |
| DK (2) | DK3332789T3 (en) |
| EA (1) | EA015799B1 (en) |
| ES (1) | ES2921858T3 (en) |
| FR (1) | FR18C1008I2 (en) |
| HR (1) | HRP20120228T1 (en) |
| HU (2) | HUE059133T2 (en) |
| IL (2) | IL183930A0 (en) |
| LT (2) | LT3332789T (en) |
| LU (1) | LUC00064I2 (en) |
| MX (1) | MX2007007610A (en) |
| NO (1) | NO20073813L (en) |
| PL (3) | PL1827461T3 (en) |
| SG (1) | SG160391A1 (en) |
| SI (2) | SI2805723T1 (en) |
| WO (1) | WO2006067141A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009537605A (en) | 2006-05-24 | 2009-10-29 | メルク セローノ ソシエテ アノニム | Cladribine regimen for the treatment of multiple sclerosis |
| EP2343074A1 (en) | 2009-12-23 | 2011-07-13 | Merck Serono S.A. | Use of purine analogues for treating airway diseases |
| WO2011117267A1 (en) | 2010-03-24 | 2011-09-29 | Merck Serono Sa | Cladribine treatment of multiple sclerosis in patient groups defined by genotype |
| EP2428201A1 (en) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Oral administration of nucleoside monophosphates |
| WO2012097867A1 (en) | 2011-01-18 | 2012-07-26 | Synthon Bv | Cladribine particles and pharmaceutical compositions comprising them |
| GB201401465D0 (en) | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
| GB2564717A (en) * | 2017-07-21 | 2019-01-23 | Chord Therapeutics S A R L | Use of cladribine for treating autoimmune neuromuscular disease |
| MX2020005266A (en) * | 2017-11-24 | 2020-09-18 | Merck Patent Gmbh | Cladribine regimen for use intreating progressive forms of multiple sclerosis. |
| GB2601786A (en) | 2020-12-10 | 2022-06-15 | Chord Therapeutics S A R L | Use of cladribine for treating immune brain disease |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
| US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US4964848A (en) * | 1988-06-27 | 1990-10-23 | Bloom Philip M | Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression |
| US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5641757A (en) | 1994-12-21 | 1997-06-24 | Ortho Pharmaceutical Corporation | Stable 2-chloro-2'-deoxyadenosine formulations |
| JPH10512549A (en) | 1994-12-22 | 1998-12-02 | オーソ・フアーマシユーチカル・コーポレーシヨン | Soluble 2-chloro-2'-deoxyadenosine formulation |
| US6194395B1 (en) | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| WO2000064918A1 (en) | 1999-04-28 | 2000-11-02 | Sterrenbeld Biotechnologie North America, Inc. | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE |
| DE10237146A1 (en) * | 2002-08-13 | 2004-03-04 | Medac Gesellschaft für klinische Spezialpräparate mbH | Use of treosulfan and derivatives thereof for the treatment of multiple sclerosis |
| AU2003275267A1 (en) | 2002-09-25 | 2004-04-19 | Brigham Young University, Technology Transfer Office | Method for the preparation of 2-halo-2'-deoxyadenosine compounds from 2'-deoxyguanosine |
| GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| CN1761471A (en) * | 2003-02-25 | 2006-04-19 | 应用研究系统Ars股份公司 | Combined use of ribavirin and interferon beta in demyelinating diseases |
| EA009714B1 (en) | 2003-03-28 | 2008-02-28 | Арес Трейдинг С.А. | Cladribine formulations for improved oral and transmucosal delivery |
| SG175450A1 (en) | 2003-03-28 | 2011-11-28 | Ares Trading Sa | Oral formulations of cladribine |
| JP2009537605A (en) * | 2006-05-24 | 2009-10-29 | メルク セローノ ソシエテ アノニム | Cladribine regimen for the treatment of multiple sclerosis |
-
2005
- 2005-12-20 EP EP05823474A patent/EP1827461B1/en active Active
- 2005-12-20 KR KR1020077016508A patent/KR20070091662A/en not_active Application Discontinuation
- 2005-12-20 CA CA2588966A patent/CA2588966C/en active Active
- 2005-12-20 EP EP10182676.6A patent/EP2263678B1/en active Active
- 2005-12-20 HU HUE18151634A patent/HUE059133T2/en unknown
- 2005-12-20 JP JP2007547486A patent/JP5795456B2/en active Active
- 2005-12-20 SI SI200532191T patent/SI2805723T1/en unknown
- 2005-12-20 SG SG201001736-6A patent/SG160391A1/en unknown
- 2005-12-20 DK DK18151634.5T patent/DK3332789T3/en active
- 2005-12-20 PL PL05823474T patent/PL1827461T3/en unknown
- 2005-12-20 DK DK14001970.4T patent/DK2805723T3/en active
- 2005-12-20 SI SI200532305T patent/SI3332789T1/en unknown
- 2005-12-20 BR BRPI0517132A patent/BRPI0517132B8/en active IP Right Grant
- 2005-12-20 PL PL14001970T patent/PL2805723T3/en unknown
- 2005-12-20 AU AU2005318190A patent/AU2005318190B2/en active Active
- 2005-12-20 EP EP14001970.4A patent/EP2805723B1/en not_active Revoked
- 2005-12-20 US US11/722,018 patent/US7713947B2/en active Active
- 2005-12-20 PL PL18151634.5T patent/PL3332789T3/en unknown
- 2005-12-20 EP EP18151634.5A patent/EP3332789B1/en active Active
- 2005-12-20 ES ES18151634T patent/ES2921858T3/en active Active
- 2005-12-20 EP EP10182632.9A patent/EP2275110B1/en active Active
- 2005-12-20 MX MX2007007610A patent/MX2007007610A/en unknown
- 2005-12-20 LT LTEP18151634.5T patent/LT3332789T/en unknown
- 2005-12-20 EA EA200701221A patent/EA015799B1/en active Protection Beyond IP Right Term
- 2005-12-20 EP EP22166610.0A patent/EP4070800A1/en active Pending
- 2005-12-20 WO PCT/EP2005/056954 patent/WO2006067141A1/en active Application Filing
- 2005-12-20 CA CA3087419A patent/CA3087419C/en active Active
- 2005-12-21 AR ARP050105411A patent/AR052830A1/en not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183930A patent/IL183930A0/en active IP Right Grant
- 2007-07-20 NO NO20073813A patent/NO20073813L/en not_active Application Discontinuation
-
2010
- 2010-04-23 US US12/766,173 patent/US8377903B2/en active Active
-
2011
- 2011-02-23 AU AU2011200768A patent/AU2011200768B2/en active Active
- 2011-04-17 IL IL212421A patent/IL212421A/en active IP Right Grant
-
2012
- 2012-03-13 HR HR20120228T patent/HRP20120228T1/en unknown
- 2012-04-11 CY CY20121100358T patent/CY1112614T1/en unknown
-
2013
- 2013-05-30 JP JP2013113850A patent/JP5908863B2/en active Active
-
2015
- 2015-06-16 JP JP2015120875A patent/JP6092945B2/en active Active
-
2016
- 2016-04-08 JP JP2016078293A patent/JP6290962B2/en active Active
-
2017
- 2017-02-09 JP JP2017022375A patent/JP6430554B2/en active Active
-
2018
- 2018-01-18 CY CY20181100065T patent/CY1119790T1/en unknown
- 2018-02-12 LU LU00064C patent/LUC00064I2/fr unknown
- 2018-02-14 FR FR18C1008C patent/FR18C1008I2/en active Active
- 2018-02-15 HU HUS1800009C patent/HUS1800009I1/en unknown
- 2018-02-20 LT LTPA2018503C patent/LTC2805723I2/en unknown
- 2018-02-28 CY CY2018006C patent/CY2018006I1/en unknown
- 2018-07-09 JP JP2018129918A patent/JP2018165271A/en active Pending
-
2020
- 2020-08-06 JP JP2020134010A patent/JP2020193206A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR18C1008I2 (en) | CLADRIBINE DOSAGE REGIMEN FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
| FR23C1003I2 (en) | Compositions and their uses for the treatment of Multiple Sclerosis | |
| EP1789086A4 (en) | Extended treatment of multiple sclerosis | |
| FR2907011B1 (en) | USE OF CITRULLINE FOR THE TREATMENT OF DENUTRITION CONDITIONS | |
| MA27395A1 (en) | USE OF PREBIOTICS FOR THE TREATMENT AND PREVENTION OF HYPER-GLYCEMIC SYNDROMES | |
| EP1827491A4 (en) | Treatment for multiple sclerosis | |
| EP1750513A4 (en) | Use of gpcr54 ligands for the treatment of infertility | |
| MA29097B1 (en) | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS BY FLAVIVIRIDAE | |
| IL178846A0 (en) | Solid dosage form of wetted heparin | |
| FR2900341B1 (en) | USE OF MULTIVALENT SYNTHETIC LIGANDS OF SURFACE NUCLEOLIN FOR THE TREATMENT OF CANCER | |
| IL179337A0 (en) | Pharmaceutical compositions for the treatment of pruritus | |
| AP2910A (en) | Novel use of antihistamine agents for the preventative or early treatment of inflammatory syndromes,in particular those triggered by togaviruses | |
| FR2886153B1 (en) | COMPOSITION FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
| FR2899128B1 (en) | USE OF DELEUCOCYTATION FILTERS FOR THE PURIFICATION OF DEFENSINS | |
| FR2905868B1 (en) | COMPOSITION FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | |
| FR2910813B1 (en) | NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA | |
| FR2901703B1 (en) | USE OF ZATOSETRON FOR THE TREATMENT OF ROSACEA, AND PHARMACEUTICAL COMPOSITIONS | |
| FR2868312B1 (en) | PATCH FOR THE TREATMENT OF LIP | |
| FR2962041B1 (en) | INHIBITORS OF CALPAIN 3 FOR THE TREATMENT OF MUSCULAR DYSTROPHIES AND CARDIOMYOPATHIES | |
| FR2875404B1 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ROSACEA | |
| HK1130008A1 (en) | Use of thymosin alpha 1 for the treatment of immunological diseases | |
| FR2937550B1 (en) | USE OF CITRULLINE FOR THE TREATMENT AND PREVENTION OF ISCHEMIA-REPERFUSION SYNDROME | |
| FR2902321B1 (en) | USE OF CURCUMIN FOR THE TREATMENT OF CANITIA | |
| FR2915099B1 (en) | USE OF 4-CYCLOPROPYLMETHOXY-N- (3,5-DICHLORO-1-OXYDO-PYRIDIN-4-YL) -5- (METHOXY) PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF CRANIAL TRAUMATISM | |
| FR2878160B1 (en) | USE OF MAGNESIUM N-ACETYL TAURINATE FOR THE PREPARATION OF INHIBITORY DRUGS FOR PHOTIC HYPERSENSIBLITY |